The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced ...

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...

In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting ...

Pfizer Inc. PFE on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regimen demonstrated a statistically significant ...

The intestinal epithelium undergoes rapid renewal every 3–5 days, a process driven by intestinal stem cells (ISCs) located at the base of crypts.